Pricing changes frequently. We reviewed the sections below against manufacturer and CMS sources; the section dates identify when prices were checked. Your pharmacy cost depends on eligibility, dose, device and coverage. PEAK verifies your specific coverage and expected out-of-pocket cost before treatment begins.

Lowest cash-pay price at a glance

These are entry-dose manufacturer self-pay offers checked November 4, 2026. Eligibility restrictions apply, starting doses may not be maintenance doses, and your ongoing cost may be higher. Compare dose-specific details below and confirm the final pharmacy charge.

Wegovy
semaglutide · Novo Nordisk
$149/mo
1.5 mg oral tablet: $149 for 30 days. Injection: eligible new patients pay $199 for each of two low-dose 28-day fills through December 31, 2026; then $349 (HD: $399).
Zepbound
tirzepatide · Eli Lilly
$299/mo
Single-dose vials or KwikPen: $299 at 2.5 mg; $399 at 5 mg; $449 at higher doses under the Journey offer. Higher-dose refill purchases must be within 45 days of the previous delivery or receipt.
Ozempic
semaglutide · Novo Nordisk
$199/mo
Eligible new patients: $199 for each of two 0.25/0.5 mg pen fills through December 31, 2026. Then $349 for 0.25/0.5/1 mg or $499 for 2 mg. Prior-use restrictions apply.
Mounjaro
tirzepatide · Eli Lilly
From $499/mo
LillyDirect single-dose pens for eligible adults with an FDA-labeled use, paid outside insurance. Commercial copay assistance is a separate offer.

Wegovy (semaglutide) — Novo Nordisk

Wegovy is FDA-approved for chronic weight management and is available as both an injection pen and an oral tablet. Novo Nordisk offers several self-pay pricing tiers depending on the form factor and dosage.

Injection Pens

Checked November 4, 2026
Dosage List Price Self-Pay (NovoCare) Eligible covered-commercial offer
0.25 mg (month 1) $1,349.02/mo $199/mo Eligible new patients: first 2 fills through Dec 31, 2026; then $349 As low as $25/mo
0.5 mg (month 2) $1,349.02/mo $199/mo Eligible new patients: first 2 fills through Dec 31, 2026; then $349 As low as $25/mo
1 mg $1,349.02/mo $349/mo As low as $25/mo
1.7 mg $1,349.02/mo $349/mo As low as $25/mo
2.4 mg (maintenance) $1,349.02/mo $349/mo As low as $25/mo

Sources: Wegovy offer terms and manufacturer list prices, checked November 4, 2026. Eligible new patients pay $199 for each of their first two 28-day fills at 0.25 mg or 0.5 mg through December 31, 2026. Prior-use exclusions apply. Standard self-pay is $349 per 28 days at 0.25–2.4 mg or $399 for HD 7.2 mg. Self-pay purchases operate outside insurance and cannot be submitted for reimbursement or credited to deductibles or out-of-pocket limits.

Oral Tablets (Wegovy Pill)

Checked November 4, 2026
Dosage List Price Self-Pay Notes
1.5 mg tablet $1,349.02/mo $149/mo Current standard self-pay offer
4 mg tablet $1,349.02/mo $199/mo Current standard self-pay offer
9 mg tablet $1,349.02/mo $299/mo —
25 mg tablet $1,349.02/mo $299/mo —

Sources: Wegovy offer terms and manufacturer list prices, checked November 4, 2026. The tablet self-pay offer is $149 at 1.5 mg, $199 at 4 mg and $299 at 9 mg or 25 mg, per bottle of 30 tablets. The list price is $1,349.02 per package; list price is not a pharmacy quote.

For details on the Wegovy savings card for commercially insured patients, see our Wegovy Savings Card guide.

Zepbound (tirzepatide) — Eli Lilly

Zepbound is FDA-approved for weight management. Lilly offers several self-pay and commercial savings pathways. Compare the specific device and eligibility terms; list prices do not establish your pharmacy cost.

Injection Pens (Retail Pharmacy)

Reviewed November 4, 2026
Dosage List Price Pharmacy cash price Eligible covered-commercial offer
2.5 mg See product range below Request pharmacy quote As low as $25/mo
5 mg See product range below Request pharmacy quote As low as $25/mo
7.5 mg See product range below Request pharmacy quote As low as $25/mo
10 mg See product range below Request pharmacy quote As low as $25/mo
12.5 mg See product range below Request pharmacy quote As low as $25/mo
15 mg See product range below Request pharmacy quote As low as $25/mo

Lilly publishes a Zepbound list-price range of $499–$1,086.37 per fill without mapping that range to each dose in this guide. A list price is not a pharmacy quote or a self-pay offer. Manufacturer list-price information, checked November 4, 2026.

Single-Dose Vials and KwikPen (LillyDirect)

Checked November 4, 2026

Self-pay vial and KwikPen options. Compare device preference, pharmacy availability and the current offer terms. Higher-dose Journey pricing requires a refill purchase within 45 days of the previous delivery or receipt.

Dosage LillyDirect Price If refill > 45 days
2.5 mg $299/mo $299/mo
5 mg $399/mo $399/mo
7.5 mg $449/mo $499/mo
10 mg $449/mo $699/mo
12.5 mg $449/mo $699/mo
15 mg $449/mo $699/mo

Source: Lilly’s current Zepbound terms, checked November 4, 2026. A month is 28 days: four single-dose vials or one KwikPen. The first higher-dose Journey fill is $449; continued $449 pricing requires each refill purchase within 45 days of the previous delivery or receipt. Otherwise regular prices are $499 at 7.5 mg and $699 at 10/12.5/15 mg. Additional taxes or fees may apply.

For details on the Zepbound savings card for commercially insured patients, see our Zepbound Savings Program guide.

Ozempic (semaglutide) — Novo Nordisk

Ozempic is FDA-approved for type 2 diabetes, not weight management. Some providers prescribe it off-label for weight loss. Insurance coverage for weight loss use is typically more limited than for Wegovy.

Checked November 4, 2026
Dosage List Price Self-Pay (NovoCare) Eligible covered-commercial offer
0.25 mg / 0.5 mg pen $1,027.51/mo $199/mo Eligible new patients: first 2 fills through Dec 31, 2026; then $349 As low as $25/mo
1 mg pen $1,027.51/mo $349/mo As low as $25/mo
2 mg pen $1,027.51/mo $499/mo As low as $25/mo

Sources: Ozempic list prices and current offer terms, checked November 4, 2026. The pen list price is $1,027.51 per package. Eligible new patients pay $199 for each of two low-dose pen fills through December 31, 2026; use of an Ozempic savings offer or NovoCare Pharmacy in the previous 365 days excludes this introductory offer. Standard self-pay is $349 for 0.25/0.5/1 mg pens or $499 for 2 mg. A monthly offer covers one box for 28 days. FDA-labeled use and other eligibility rules apply; self-pay purchases cannot be billed to insurance or credited to insurance spending limits. Separate PAP eligibility may apply to qualifying uninsured patients.

For details on the Ozempic savings card, see our Ozempic Savings Card guide.

Mounjaro (tirzepatide) — Eli Lilly

Mounjaro is FDA-approved for type 2 diabetes and contains the same active ingredient (tirzepatide) as Zepbound. LillyDirect advertises self-pay single-dose pens starting at $499 per month across the six strengths, subject to eligibility; list prices and copay cards are separate.

Checked November 4, 2026
Dosage Self-pay (LillyDirect) Eligible covered-commercial offer
2.5 mg LillyDirect from $499/mo; terms apply As low as $25/mo
5 mg LillyDirect from $499/mo; terms apply As low as $25/mo
7.5 mg LillyDirect from $499/mo; terms apply As low as $25/mo
10 mg LillyDirect from $499/mo; terms apply As low as $25/mo
12.5 mg LillyDirect from $499/mo; terms apply As low as $25/mo
15 mg LillyDirect from $499/mo; terms apply As low as $25/mo

Lilly publishes Mounjaro list-price information separately from patient offers. LillyDirect advertises single-dose pens starting at $499/month for eligible adults prescribed it for an FDA-labeled use. Cash purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. A separate commercial savings-card pathway may reduce costs for eligible patients. Check the program, prescription and pharmacy requirements before filling.

For details on the Mounjaro savings card, see our Mounjaro Savings Card guide.

Savings programs at a glance

These are advertised minimum patient prices, not guaranteed copays. Commercial copay offers require coverage of the prescribed drug and exclude government-insured patients. Savings caps may leave you owing more. Self-pay programs have separate eligibility rules. Office visits, labs and other services are separate.

Each manufacturer offers programs to help reduce out-of-pocket costs. Eligibility and terms differ between the two companies.

Program Who Qualifies Copay Max Savings
Wegovy Savings Card Eligible commercial insurance with drug coverage As little as $25; caps apply $100/mo
Zepbound Savings Card Commercially insured with coverage As little as $25; caps apply $100/mo ($1,300/yr)
Ozempic Savings Card Eligible commercial insurance with drug coverage As little as $25; caps apply $100 per month of supply; card activation up to 48 months; terms can change
Mounjaro Savings Card Eligible commercial insurance with drug coverage As little as $25; caps apply $150/mo ($1,950/yr)
LillyDirect Vials / KwikPen (Zepbound) Eligible patients buying outside insurance; prescription and program terms apply $299–$449/mo Dose and offer dependent
NovoCare Self-Pay (Wegovy) Eligible patients buying outside insurance; prescription and program terms apply $149–$399/mo Dose and offer dependent

Medicare and Medicaid: Commercial copay offers exclude government beneficiaries. Separate cash programs may permit eligible patients to purchase outside insurance without reimbursement or spending-limit credit. The Medicare GLP-1 Bridge runs July 1, 2026 through December 31, 2027, outside regular Part D, and offers qualifying medicines for $50/month subject to eligible plan enrollment, prior authorization and CMS clinical criteria. Covered formulations include Foundayo, Wegovy injection/tablets and Zepbound KwikPen. See CMS rules. PEAK does not accept Medicare or Medicaid.

How PEAK helps with cost

PEAK does not sell medication directly. Our team helps you compare applicable insurance benefits, manufacturer programs and pharmacy quotes before treatment.

For a full breakdown of PEAK visit costs (separate from medication pricing), see our Weight Loss Program Cost page.

Our goal is to make sure cost is not the reason someone gives up on treatment that is working.